Liver Cancer
Conditions
Brief summary
This study was led by the Department of Hepatobiliary Surgery of the First Affiliated Hospital of the University of Science and Technology of China (USTC), in close cooperation with many participating units across the country, to establish a standardized clinical information database of hepatocellular carcinoma cohorts, which will provide a guarantee for conducting high-quality real-world clinical studies and clinical research.
Interventions
PROCEDUREProcedure/Surgery treatment
Routine surgical operations for patients with hepatocellular carcinoma, such as surgical resection, ablation，TACE，HAIC
DRUGAnti-Tumor Drugs
Use of anti-tumor drugs, e.g., immunologic, targeted, and chemotherapy drugs
Sponsors
Anhui Provincial Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years, no gender limit * Patients without surgery are initially diagnosed with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, mixed hepatocellular carcinoma-cholangiocarcinoma, or metastatic hepatocellular carcinoma based on the results of imaging and laboratory tests, or patients with surgery are diagnosed with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, mixed hepatocellular carcinoma-cholangiocarcinoma, or metastatic hepatocellular carcinoma based on the results of pathologic tests * Signed informed consent, good compliance, willingness to accept follow-up and provide blood and postoperative pathology residual samples
Exclusion criteria
* Combination of severe central nervous system disease, respiratory disease, autoimmune disease, chronic renal insufficiency, long-term use of immunosuppressive drugs, combination of severe uncontrolled infections * Concurrent active cardiovascular disease, cerebrovascular accident within 6 months, myocardial infarction, unstable angina pectoris, or congestive heart failure of class II or greater according to the New York Heart Association criteria, severe arrhythmia requiring medication * Pregnant or breastfeeding women * Participation in other therapeutic clinical trials during the course of the patient's illness in which the treatment cannot be specified or information about the treatment cannot be collected
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| OS | 10 years | Time from enrollment to first recorded occurrence of death from any cause |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| RFS | 10 years | Time from enrollment to the first documented occurrence of local, regional, or metastatic liver cancer or death from any cause, whichever occurs first. |
| Survival time after recurrence | 10 years | The time from the first documented occurrence of localized, regional, or metastatic liver cancer, whichever occurs first, to death from any cause. |
Countries
China
Contacts
Primary ContactJi-Zhou Wang, MD PhD
Backup ContactLianxin Liu, MD PhD
Outcome results
None listed